ECSP034692A - HISTAMINE RECEIVER ANTAGONISTS - Google Patents

HISTAMINE RECEIVER ANTAGONISTS

Info

Publication number
ECSP034692A
ECSP034692A EC2003004692A ECSP034692A ECSP034692A EC SP034692 A ECSP034692 A EC SP034692A EC 2003004692 A EC2003004692 A EC 2003004692A EC SP034692 A ECSP034692 A EC SP034692A EC SP034692 A ECSP034692 A EC SP034692A
Authority
EC
Ecuador
Prior art keywords
histamine
receptor
receiver antagonists
histamine receiver
antagonists
Prior art date
Application number
EC2003004692A
Other languages
Spanish (es)
Inventor
Stephen Jenkinson
Mark Anthony O'reilly
Michael Andrew Trevethick
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP034692A publication Critical patent/ECSP034692A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una combinación de (a) un antagonista de receptor H1 de histamina y (b) un antagonista que es al menos 10 veces más selectivo para el receptor H4 de histamina en comparación con el receptor H3 de histamina que es al menos 10 veces más selectivo para el receptor H4 de histamina en comparación con el receptor 3 de histamina; y sus composiciones y usos.The present invention provides a combination of (a) a histamine H1 receptor antagonist and (b) an antagonist that is at least 10 times more selective for the histamine H4 receptor compared to the histamine H3 receptor that is at least 10 times more selective for the histamine H4 receptor compared to the histamine receptor 3; and its compositions and uses.

EC2003004692A 2001-01-17 2003-07-17 HISTAMINE RECEIVER ANTAGONISTS ECSP034692A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0101223.6A GB0101223D0 (en) 2001-01-17 2001-01-17 Histamine receptor antagonists

Publications (1)

Publication Number Publication Date
ECSP034692A true ECSP034692A (en) 2003-08-29

Family

ID=9906993

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004692A ECSP034692A (en) 2001-01-17 2003-07-17 HISTAMINE RECEIVER ANTAGONISTS

Country Status (32)

Country Link
EP (1) EP1353657A1 (en)
JP (1) JP2004517883A (en)
KR (1) KR20030069216A (en)
CN (1) CN1486178A (en)
AP (1) AP2002002401A0 (en)
AR (1) AR032101A1 (en)
BG (1) BG107834A (en)
BR (1) BR0206502A (en)
CA (1) CA2435121A1 (en)
CR (1) CR6983A (en)
CZ (1) CZ20031853A3 (en)
DO (1) DOP2002000325A (en)
EA (1) EA200300537A1 (en)
EC (1) ECSP034692A (en)
EE (1) EE200300335A (en)
GB (1) GB0101223D0 (en)
GT (1) GT200200003A (en)
HU (1) HUP0302767A2 (en)
IL (1) IL156087A0 (en)
IS (1) IS6818A (en)
MA (1) MA26980A1 (en)
MX (1) MXPA03006408A (en)
NO (1) NO20033223L (en)
OA (1) OA12440A (en)
PA (1) PA8537101A1 (en)
PL (1) PL362793A1 (en)
PY (1) PY0200477A (en)
SK (1) SK8572003A3 (en)
SV (1) SV2003000849A (en)
TN (1) TNSN02003A1 (en)
WO (1) WO2002056871A2 (en)
ZA (1) ZA200304180B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133931A1 (en) * 2001-12-21 2003-07-17 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
MXPA05002577A (en) * 2002-09-06 2005-09-20 Johnson & Johnson Use of histamine h4 receptor modulators for the treatment of allergy and asthma.
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
CN119823227B (en) * 2025-01-14 2025-07-04 广州迪卡德营养科技有限公司 A preparation method of probiotics and use thereof in treating allergic rhinitis

Also Published As

Publication number Publication date
ZA200304180B (en) 2004-06-15
CZ20031853A3 (en) 2004-07-14
KR20030069216A (en) 2003-08-25
HUP0302767A2 (en) 2003-11-28
TNSN02003A1 (en) 2005-12-23
CR6983A (en) 2003-11-25
OA12440A (en) 2006-05-22
SV2003000849A (en) 2003-01-13
AR032101A1 (en) 2003-10-22
EE200300335A (en) 2003-12-15
GB0101223D0 (en) 2001-02-28
EA200300537A1 (en) 2004-02-26
JP2004517883A (en) 2004-06-17
CN1486178A (en) 2004-03-31
EP1353657A1 (en) 2003-10-22
PY0200477A (en) 2004-06-01
BR0206502A (en) 2003-10-21
WO2002056871A2 (en) 2002-07-25
PL362793A1 (en) 2004-11-02
CA2435121A1 (en) 2002-07-25
GT200200003A (en) 2002-08-19
AP2002002401A0 (en) 2002-03-31
BG107834A (en) 2004-01-30
PA8537101A1 (en) 2002-08-29
NO20033223D0 (en) 2003-07-16
NO20033223L (en) 2003-07-16
SK8572003A3 (en) 2004-07-07
DOP2002000325A (en) 2003-01-31
MA26980A1 (en) 2004-12-20
IS6818A (en) 2003-05-15
MXPA03006408A (en) 2003-10-15
IL156087A0 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
AU3652102A (en) Compounds and their uses
PA8567001A1 (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
DE60222396D1 (en) N- (2-ARYLETHYL) BENZYLAMINE AS 5-HT6 RECEPTOR ANTAGONIST
NO993350L (en) Vitronectin receptor antagonists
LV12639B (en) Biphenylsulfonamide is a dual angiotensin and endothelin receptor antagonist
BR0206595A (en) Compound, pharmaceutical composition, and use of a compound
MX9302618A (en) PHENYL SULFONAMIDES ENDOTHELINE ANTAGONISTS.
ECSP045274A (en) N-AMINOACETIL-PIRROLIDINA-2-CARBONITRILOS AND ITS USE AS DDP-IV INHIBITORS
IL155236A0 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
HN2002000299A (en) DERIVATIVES OF 3- AZABICICLO [3.1.0] HEXANO
ES2190487T3 (en) NEW AGONISTS AND ANTAGONISTS OF THE ADENOSINE RECEIVER A1.
ECSP034531A (en) SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA
ECSP034692A (en) HISTAMINE RECEIVER ANTAGONISTS
DK1313485T3 (en) Use of an aldosterone receptor antagonist to improve cognitive function
ECSP034558A (en) STROGEN RECEIVER MODULATORS
AR031356A1 (en) LACTA MICO COMPOUND
UY26627A1 (en) IL-8 RECEPTOR ANTAGONISTS
UY27124A1 (en) HISTAMINE RECEIVER ANTAGONISTS
DK1177191T3 (en) Substituted benzimidazoles, preparation and use thereof as agents for the control of parasitic protozoa
ES2155187T3 (en) BICYCLE ANTAGONISTS OF TAQUICINAS, PREPARATION OF THESE ANTAGONISTS AND ITS USE IN PHARMACEUTICAL COMPOUNDS.
ATE387201T1 (en) PHARMACEUTICAL COMBINATION OF TENATOPRAZOLE AND A HISTAMINE H2 RECEPTOR ANTAGONIST
UY26893A1 (en) PHARMACEUTICAL COMBINATION OF ANTAGONISTS OF ANGIOTENSIN II AND INHIBITORS OF THE CONVERSION ENZYME OF ANGIOTENSIN I
EP1117681A4 (en) Novel peptides
BR0113202A (en) Trioxepane compounds
EA200301109A1 (en) METHOD FOR ADDING EDGE EDUCATION